Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial

By sjmartinez • October 25, 2023

Rha SY, Oh DY, Yañez P, Bai Y, Ryu MH, Lee J, Rivera F, Alves GV, Garrido M, Shiu KK, Fernández MG, Li J, Lowery MA, Çil T, Cruz FM, Qin S, Luo S, Pan H, Wainberg ZA, Yin L, Bordia S, Bhagia P, Wyrwicz LS; KEYNOTE-859 investigators. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2023 Oct 19:S1470-2045(23)00515-6. doi: 10.1016/S1470-2045(23)00515-6. Epub ahead of print. PMID: 37875143.

Tags: Hematology/Oncology, Publications

Liquid Biopsy of Circulating Tumor Cells and DNA in the Context of PSMA Radiopharmaceutical Therapy

Holzgreve A, Mona CE, Kimura K, Li X, Zhu Y, Tseng HR, Lee JK, Drakaki A, Garraway IP, Rettig MB, Calais J, Salavati A. Liquid[...]

Cumulative burden of depression and domain-specific cognitive impairment over time in the women’s interagency HIV study: A marginal structural model approach

Tejera CH, Duggal P, Diaz M, Topper E, Gustafson D, Jamieson BD, Maki PM, Sharma A, Spence AB, Weber KM, Weinstein AM, Jones DL, Fazeli[...]

Characterization of the Fecal Metabolome in Patients With Early Systemic Sclerosis

Young AC, Andréasson K, Labus J, Matulionis N, Jacobs JP, Christofk H, Volkmann ER. Characterization of the Fecal Metabolome in Patients With Early Systemic Sclerosis.[...]